- Home
- Automated
- List of product information
- SWILIX SR TABLET 1.5MG [SIN16750P]
SWILIX SR TABLET 1.5MG [SIN16750P]
Active ingredients: SWILIX SR TABLET 1.5MG
Last updated 26 October 2025
On this page
Product Info
SWILIX SR TABLET 1.5MG
[SIN16750P]
Product information
Active Ingredient and Strength | INDAPAMIDE - 1.5 MG |
Dosage Form | TABLET, FILM COATED, EXTENDED RELEASE |
Manufacturer and Country | IND-SWIFT LIMITED - INDIA |
Registration Number | SIN16750P |
Licence Holder | GOLDPLUS UNIVERSAL PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | C03BA11 |
INDICATIONS & USAGE:
Indapamide Sustained Release Tablets is indicated in essential hypertension in adults.
DOSAGE & ADMINISTRATION:
Posology
One tablet per 24 hours, preferably in the morning, to be swallowed whole with water and not chewed.
At higher doses the antihypertensive action of indapamide is not enhanced but the saluretic effect is increased.
Special populations
Renal impairment:
In severe renal failure (creatinine clearance below 30 ml/min), treatment is contraindicated.
Thiazide and related diuretics are fully effective only when renal function is normal or only minimally impaired.
Hepatic impairment:
In severe hepatic impairment, treatment is contraindicated.
Elderly:
In the elderly, the plasma creatinine must be adjusted in relation to age, weight and gender. Elderly patients can be treated with Indapamide Sustained Release Tablets when renal function is normal or only minimally impaired.
Paediatric population:
The safety and efficacy of Indapamide Sustained Release Tablets in children and adolescents have not been established. No data are available.
Method of administration
Oral use
CONTRAINDICATION:
Hypersensitivity to the active substance, to other sulfonamides or to any of the excipients.
Severe renal failure.
Hepatic encephalopathy or severe impairment of liver function.
Hypokalaemia